GoldenGolden
Advanced Search
NANOVIRICIDES

NANOVIRICIDES

NanoViricides is a company developing nano-medicine therapeutics technology to fight viral diseases. The company trades on the OTC market under the symbol NNVC

NanoViricides is a company developing nano-medicine therapeutics technologies to fight viral diseases. The company was founded by Anil R. Diwan in 2005 in West Haven, Connecticut, United States.

The company looks to discover, develop, and commercialize therapeutics in order to advance the care of patients that are dealing with dangerous viral infections. The company has developed an agent known as a nanoviricide, which is designed to trick a virus into attaching it to itself which will, in turn, kill the virus. Once attached, the nanoviricide wraps around the virus and traps it, causing it to lose its coat proteins, neutralizing the virus entirely.

COVID-19

With the outbreak of COVID-19 (coronavirus), the company has began working on a treatment for the novel coronavirus since January 30, 2020. The company has completed the synthesis of a several nanoviricide drug candidates for testing after the identification of the virus binding ligands. The company has tested against two low-threat circulating coronaviruses and has expanded them to enable testing of drug candidates.

Timeline

Funding rounds

People

Name
Role
LinkedIn

Anil R. Diwan

Founder, President

Eugene Seymour

CEO

Jayant Takate

VP

Meeta R. Vyas

CFO

Randall Barton

CSO

Further reading

Title
Author
Link
Type
Date

NanoViricides Inc: A New Era in Targeted Anti-Viral Therapeutics

Your name

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

NanoViricides

Eugene Seymour

West Haven, Connecticut, United States

Biotechnology, pharmaceuticals

News

Title
Author
Date
Publisher
Description
FinancialNewsMedia.com
January 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- The antivirals market consists of sales of antiviral drugs and related services. Antiviral drugs reduce the replication of viruses at different...
BioSpace
November 19, 2020
BioSpace
NanoViricides, Inc., a leader in developing novel nanomedicines to treat viral diseases, announced that Mr. Brian Zucker, CPA, has joined the Company's Board of Directors, effective November 13, 2020, as an independent director.
BioSpace
November 11, 2020
BioSpace
NanoViricides, Inc.today reported that it has engaged Calvert Labs, a contract research organization ("CRO"), for performing the Safety Pharmacology studies of its clinical drug candidate for the treatment of COVID-19.
Alex Keown
May 22, 2020
BioSpace
Pharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
BioSpace
May 21, 2020
BioSpace
NanoViricides, Inc. a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.